TFG Asset Management’s Axsome Therapeutics AXSM Stock Holding History

TFG Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.57M	Hold	35,000	–	–	1.35%	16
2026 Q1	$5.92M	Buy	+35,000	New	+$6.05M	1.15%	13

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TFG Asset Management's AXSM Position: Q2 2026 in Review

TFG Asset Management sold out of Axsome Therapeutics (AXSM) in Q2 2026, closing a stake of 20,059 shares — an estimated $4.35M sold.

TFG Asset Management first reported a position in AXSM in Q4 2024 and held it in 6 quarters. The position peaked at $5.64M in Q3 2025. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

TFG Asset Management reported no remaining Axsome Therapeutics position as of Q2 2026 after selling out during the quarter.
TFG Asset Management sold 20,059 Axsome Therapeutics shares in Q2 2026, an estimated $4.35M.
TFG Asset Management first reported a position in Axsome Therapeutics in Q4 2024 and held it in 6 quarters.
TFG Asset Management's Axsome Therapeutics position peaked at $5.64M in Q3 2025.
505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on TFG Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.